MLYS Stock Summary and Trading Ideas (Mineralys Therapeutics | NASDAQ:MLYS)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.

As of December 13, 2024, MLYS stock price declined to $11.90 with 74,263 million shares trading.

MLYS has a beta of 2.37, meaning it tends to be more sensitive to market movements. MLYS has a correlation of 0.21 to the broad based SPY ETF.

MLYS has a market cap of $591.75 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that MLYS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

MLYS has outperformed the market in the last year with a return of +48.0%, while the SPY ETF gained +29.9%. However, in the most recent history, MLYS shares have underperformed the stock market with its stock returning +1.2% in the last 3 month period and -6.8% for the last 2 week period, while SPY has returned +7.8% and +0.3%, respectively.

MLYS support price is $11.59 and resistance is $12.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.